nach oben

Pathology & Oncology Research

Erschienen in:

01.10.2014 | Research

Screening of Critical Genes in Lung Adenocarcinoma via Network Analysis of Gene Expression Profile

verfasst von: Ping Huang, Kejian Cao, Heng Zhao

Erschienen in: Pathology & Oncology Research | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

Biomarker discovery is of great importance in diagnosis and treatment of diseases. In present study, a number of differentially expressed genes (DEGs) were identified for lung adenocarcinoma via comparative analysis of gene expression data. A gene expression core signature was generated for four types of lung adenocarcinoma (EGFR-mutated, KRAS-mutated, ALK-mutated and triple-negative adenocarcinoma). Functional enrichment analysis with DAVID tools revealed that up-regulated genes were mainly associated with cell cycle while down-regulated genes were mainly involved in vasculature development and cell adhesion. Then it was used to retrieve relevant small molecule drugs with Connectivity map and trichostatin A was predicted to be the top candidate drug for treatment of lung cancer. Network clustering was performed with MCL in cytoscape to identify sub-networks and several hub genes were obtained: CDC25C, ICT1, TK1 and EZH2. These genes play important roles in the progression of lung cancer and some have been suggested as potential biomarkers. Therefore, our findings are beneficial in deepening the understandings about the pathogenesis and providing directions for future researches.

Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N, Russo A (2010) Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev 36(Suppl 3):S21–29. doi:10.1016/S0305-7372(10)70016-5 PubMedCrossRef

Gerber DE, Minna JD (2010) ALK inhibition for non-small cell lung cancer: from discovery to therapy in record time. Cancer Cell 18(6):548–551PubMedCrossRefPubMedCentral

Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367–1380. doi:10.1056/NEJMra0802714 PubMedCrossRef

Janku F, Stewart DJ, Kurzrock R (2010) Targeted therapy in non-small-cell lung cancer–is it becoming a reality? Nat Rev Clin Oncol 7(7):401–414. doi:10.1038/nrclinonc.2010.64 PubMedCrossRef

Pao W, Girard N (2011) New driver mutations in non-small-cell lung cancer. Lancet Oncol 12(2):175–180. doi:10.1016/S1470-2045(10)70087-5 PubMedCrossRef

Dai M, Wang P, Boyd AD, Kostov G, Athey B, Jones EG, Bunney WE, Myers RM, Speed TP, Akil H, Watson SJ, Meng F (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 33(20):e175PubMedCrossRefPubMedCentral

Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4(2):249–264. doi:10.1093/biostatistics/4.2.249 PubMedCrossRef

da Huang W, Sherman BT, Lempicki RA (2009) Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4(1):44–57CrossRef

Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, Reich M, Hieronymus H, Wei G, Armstrong SA, Haggarty SJ, Clemons PA, Wei R, Carr SA, Lander ES, Golub TR (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795):1929–1935PubMedCrossRef

10.

Licata L, Briganti L, Peluso D, Perfetto L, Iannuccelli M, Galeota E, Sacco F, Palma A, Nardozza AP, Santonico E, Castagnoli L, Cesareni G (2012) MINT, the molecular interaction database: 2012 update. Nucleic Acids Res 40(Database issue):D857–861. doi:10.1093/nar/gkr930 PubMedCrossRefPubMedCentral

11.

Chatr-Aryamontri A, Breitkreutz BJ, Heinicke S, Boucher L, Winter A, Stark C, Nixon J, Ramage L, Kolas N, O’Donnell L, Reguly T, Breitkreutz A, Sellam A, Chen D, Chang C, Rust J, Livstone M, Oughtred R, Dolinski K, Tyers M (2013) The BioGRID interaction database: 2013 update. Nucleic Acids Res 41(D1):D816–823. doi:10.1093/nar/gks1158 PubMedCrossRefPubMedCentral

12.

Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, Telikicherla D, Raju R, Shafreen B, Venugopal A, Balakrishnan L, Marimuthu A, Banerjee S, Somanathan DS, Sebastian A, Rani S, Ray S, Harrys Kishore CJ, Kanth S, Ahmed M, Kashyap MK, Mohmood R, Ramachandra YL, Krishna V, Rahiman BA, Mohan S, Ranganathan P, Ramabadran S, Chaerkady R, Pandey A (2009) Human Protein Reference Database–2009 update. Nucleic Acids Res 37(Database issue):D767–772. doi:10.1093/nar/gkn892 PubMedCrossRefPubMedCentral

13.

Enright AJ, Van Dongen S, Ouzounis CA (2002) An efficient algorithm for large-scale detection of protein families. Nucleic Acids Res 30(7):1575–1584PubMedCrossRefPubMedCentral

14.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 13(11):2498–2504PubMedCrossRefPubMedCentral

15.

Zhang QC, Jiang SJ, Zhang S, Ma XB (2012) Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line. Asian Pac J Cancer Prev 13(7):3471–3476PubMedCrossRef

16.

Henry CJ (2010) Biomarkers in veterinary cancer screening: applications, limitations and expectations. Vet J 185(1):10–14PubMedCrossRef

17.

Chen ZH, Huang SQ, Wang Y, Yang AZ, Wen J, Xu XH, Chen Y, Chen QB, Wang YH, He E (2011) Serological thymidine kinase 1 is a biomarker for early detection of tumours—a health screening study on 35,365 people, using a sensitive chemiluminescent dot blot assay. Sensors 11(12):11064–11080PubMedCrossRefPubMedCentral

18.

Korkmaz T, Seber S, Okutur K, Basaran G, Yumuk F, Dane F, Ones T, Polat O, Madenci OC, Demir G, Turhal NS (2013) Serum thymidine kinase 1 levels correlates with FDG uptake and prognosis in patients with non small cell lung cancer. Biomarkers 18(1):88–94. doi:10.3109/1354750X.2012.738250 PubMedCrossRef

19.

Xu Y, Shi QL, Ma H, Zhou H, Lu Z, Yu B, Zhou X, Eriksson S, He E, Skog S (2012) High thymidine kinase 1 (TK1) expression is a predictor of poor survival in patients with pT1 of lung adenocarcinoma. Tumour Biol 33(2):475–483. doi:10.1007/s13277-011-0276-0 PubMedCrossRef

20.

Peng C-Y, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H (1997) Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. Science 277(5331):1501–1505PubMedCrossRef

21.

Krause K, Haugwitz U, Wasner M, Wiedmann M, Mössner J, Engeland K (2001) Expression of the cell cycle phosphatase cdc25C is down-regulated by the tumor suppressor protein p53 but not by p73. Biochem Biophys Res Commun 284(3):743–750PubMedCrossRef

22.

Carmazzi Y, Iorio M, Armani C, Cianchetti S, Raggi F, Neri T, Cordazzo C, Petrini S, Vanacore R, Bogazzi F, Paggiaro P, Celi A (2012) The mechanisms of nadroparin-mediated inhibition of proliferation of two human lung cancer cell lines. Cell Prolif 45(6):545–556. doi:10.1111/j.1365-2184.2012.00847.x PubMedCrossRef

23.

Li QQ, Wang G, Huang F, Li JM, Cuff CF, Reed E (2013) Sensitization of lung cancer cells to cisplatin by beta-elemene is mediated through blockade of cell cycle progression: antitumor efficacies of beta-elemene and its synthetic analogs. Med Oncol 30(1):488. doi:10.1007/s12032-013-0488-9 PubMedCrossRef

24.

van Belzen N, Diesveld MP, van der Made AC, Nozawa Y, Dinjens WN, Vlietstra R, Trapman J, Bosman FT (1995) Identification of mRNAs that show modulated expression during colon carcinoma cell differentiation. Eur J Biochem 234(3):843–848PubMedCrossRef

25.

van Belzen N, Dinjens WN, Eussen BH, Bosman FT (1998) Expression of differentiation-related genes in colorectal cancer: possible implications for prognosis. Histol Histopathol 13(4):1233–1242PubMed

26.

Handa Y, Hikawa Y, Tochio N, Kogure H, Inoue M, Koshiba S, Guntert P, Inoue Y, Kigawa T, Yokoyama S, Nameki N (2010) Solution structure of the catalytic domain of the mitochondrial protein ICT1 that is essential for cell vitality. J Mol Biol 404(2):260–273. doi:10.1016/j.jmb.2010.09.033 PubMedCrossRef

27.

Richter R, Rorbach J, Pajak A, Smith PM, Wessels HJ, Huynen MA, Smeitink JA, Lightowlers RN, Chrzanowska-Lightowlers ZM (2010) A functional peptidyl-tRNA hydrolase, ICT1, has been recruited into the human mitochondrial ribosome. EMBO J 29(6):1116–1125. doi:10.1038/emboj.2010.14 PubMedCrossRefPubMedCentral

28.

Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA (2006) EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24(2):268–273PubMedCrossRef

29.

Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA, Ghosh D, Sewalt RG, Otte AP, Hayes DF (2003) EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100(20):11606–11611PubMedCrossRefPubMedCentral

30.

Weikert S, Christoph F, Köllermann J, Müller M, Schrader M, Miller K, Krause H (2005) Expression levels of the EZH2 polycomb transcriptional repressor correlate with aggressiveness and invasive potential of bladder carcinomas. Int J Mol Med 16(2):349PubMed

31.

Cao W, Ribeiro Rde O, Liu D, Saintigny P, Xia R, Xue Y, Lin R, Mao L, Ren H (2012) EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer. PLoS One 7(12):e52984PubMedCrossRefPubMedCentral

32.

Lin YW, Ren LL, Xiong H, Du W, Yu YN, Sun TT, Weng YR, Wang ZH, Wang JL, Wang YC, Cui Y, Sun DF, Han ZG, Shen N, Zou WP, Xu J, Chen HY, Cao WB, Hong J, Fang JY (2013) Role of STAT3 and Vitamin D Receptor in EZH2-mediated invasion of human colorectal cancer. J Pathol. doi:10.1002/path.4179

33.

Zhang J-G, Guo J-F, Liu D-L, Liu Q, Wang J-J (2011) MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol 6(4):671–678PubMedCrossRef

Titel: Screening of Critical Genes in Lung Adenocarcinoma via Network Analysis of Gene Expression Profile
verfasst von: Ping Huang
Kejian Cao
Heng Zhao
Publikationsdatum: 01.10.2014
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 4/2014
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-014-9764-z

Springer Medizin

Screening of Critical Genes in Lung Adenocarcinoma via Network Analysis of Gene Expression Profile

Abstract

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2014

Regional Bias of Intratumoral Genetic Heterogeneity of Nucleotide Repeats in Colon Cancers with Microsatellite Instability

mTOR Pathway As a Potential Target In a Subset of Human Medulloblastoma

Tricellulin Expression and its Prognostic Significance in Primary Liver Carcinomas

Decreased Expression of NPRL2 in Renal Cancer Cells is Associated with Unfavourable Pathological, Proliferation and Apoptotic Features

Setting Up a Probe Based, Closed Tube Real-Time PCR Assay for Focused Detection of Variable Sequence Alterations

Treatment of Refractory Hairy Cell Leukemia with a BRAF-inhibitor: Lessons to be Learnt

Neu im Fachgebiet Onkologie

Erhöhte Mortalität bei postpartalem Brustkrebs

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

Update Onkologie